BrainStorm Cell Therapeutics announced that Dimitrios Karussis, principal investigator of the company’s clinical trials at Hadassah Medical Center in Jerusalem, presented his preliminary findings from the ongoing phase IIa dose-escalating trial evaluating NurOwn technology, at the 24th International Symposium on ALS/MND in Milan, Italy.
According to Karussis, the safety data are “impressively positive”, with minimal and transient adverse events, even though the patients in this study were injected both intrathecally and intramuscularly with up to double the dose of NurOwn cells given in the phase I trial. In addition, a number of patients showed some initial indications of clinical improvement. “These safety observations and initial indications of clinical efficacy are extremely optimistic for the future management of ALS and the future of cell therapies for neurodegenerative diseases in general,” Karussis comments.
The trial is currently ongoing and final data are not yet available for publication.
